Growth
Small Caps with Growth
7 Hits · last calculated September 18, 2026 Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Market filter active: the list shows 7 hits from US
Methodology & criteria
Small-cap stocks with combined earnings and revenue strength: quarterly EPS (earnings per share) ≥ 30% and quarterly revenue ≥ 30% with an EPS rating ≥ 85 — limited to a market cap between $10 million and $500 million.
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); names after a reverse split (distorted price history) are excluded.
🔔 Watch scanner
Hit List
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Volatility | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Growth Score | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELA Envela Corp | 08/05 | +95 % | 71 % | Stage 2 | A 75 | 8 of 9 | 0.4 $ | Luxury Goods | Neutral | — | Consumer Cyclical | 13.70 $ | +100.4 % | +120.5 % | +84.5 % | −9.2 % | +92.3 % | 96 | 92 | 6.6 % | 6.7 % | 0.37 | 18.6 | 54.1 | 1.2 | 5.1 | 14.8 | — | 10.3 | — | 21.7 % | 7.6 % | 32.0 % | 18.4 % | 0.26 | — | +33.6 % | 5 | 0.0 % | 0.0 % | 11.9 | 19.6 % | 7.0 % | 5.0 (2) | |
| FATN FatPipe, Inc. | 11/02 | — | ⚠ Wildest 10% 139 % | Stage 2 | B 74 | 7 of 9 | 0.1 $ | Software - Infrastructure | Neutral | — | — | Technology | 5.60 $ | +170.0 % | +158.6 % | -4.6 % | −48.5 % | +81.8 % | 92 | 93 | 10.2 % | 16.6 % | — | 15.7 | 12.1 | 4.3 | 3.1 | — | — | 19.4 | — | 90.7 % | 26.8 % | 24.2 % | 6.5 % | 0.23 | — | +17.9 % | 5 | 0.0 % | 0.0 % | 10.7 | 2.7 % | 1.2 % | — |
| FGBI First Guaranty Bancshares, Inc. | 08/17 | -3 % | 60 % | Stage 2 | C 50 | 8 of 9 | 0.1 $ | Banks - Regional | Neutral | — | — | Financial Services | 8.70 $ | +95.2 % | +114.1 % | +7.5 % | −11.9 % | +5.9 % | 82 | 92 | 5.5 % | 4.8 % | 0.43 | — | 11.7 | — | 0.8 | 3.7 | — | 0.0 | — | 100.0 % | -96.5 % | -19.8 % | -0.9 % | 0.88 | — | -20.0 % | 3 | 0.5 % | 200.0 % | 4.5 | 5.2 % | 7.6 % | 3.0 (1) |
| FNWB First Northwest Bancorp | 07/23 | 0 % | 27 % | Stage 2 | C 47 | 7 of 9 | 0.1 $ | Banks - Regional | – | — | — | Financial Services | 10.00 $ | +10.4 % | +7.9 % | +36.3 % | −5.2 % | +51.5 % | 69 | 93 | 3.0 % | 3.0 % | 0.63 | 18.2 | 0.0 | — | 0.6 | 5.0 | — | 0.0 | — | 100.0 % | 2.2 % | 3.2 % | 0.1 % | 2.19 | — | -8.4 % | 3 | 0.0 % | 0.0 % | -1.7 | 39.0 % | 0.8 % | 4.0 (2) |
| ECBK ECB Bancorp Inc. | 07/23 | +18 % | 25 % | Stage 2 | B 70 | 7 of 9 | 0.2 $ | Banks - Regional | Neutral | — | — | Financial Services | 20.80 $ | +15.8 % | +16.3 % | +29.3 % | −5.9 % | — | 66 | 88 | 3.2 % | 2.8 % | 0.45 | 17.9 | 0.0 | 2.9 | 1.0 | 8.4 | — | 0.0 | — | 100.0 % | 29.9 % | 5.6 % | 0.7 % | 1.48 | — | +16.5 % | 6 | 0.0 % | 0.0 % | — | 30.6 % | 2.1 % | — |
| AVIR Atea Pharmaceuticals Inc | 08/06 | +4 % | 50 % | Stage 2 | D 42 | 2 of 9 | 0.4 $ | Biotechnology | Uses AI | — | — | Healthcare | 5.30 $ | +25.5 % | +27.3 % | +80.8 % | −32.6 % | +81.1 % | 62 | 92 | 4.7 % | 4.7 % | 0.29 | — | 0.0 | — | 1.9 | — | — | -260.5 | — | -80.7 % | 0.0 % | -52.6 % | -36.7 % | 0.00 | — | -100.0 % | 4 | 0.0 % | 0.0 % | 4.8 | 80.1 % | 12.3 % | 3.3 (3) |
| AXR AMREP Corporation | 07/24 | +17 % | 42 % | Stage 2 | D 42 | 9 of 9 | 0.1 $ | Real Estate - Development | Neutral | — | — | Real Estate | 23.30 $ | +40.5 % | +34.4 % | -7.2 % | −11.8 % | -2.2 % | 46 | 93 | 3.8 % | 4.2 % | 1.10 | 9.4 | 37.6 | 3.1 | 0.9 | — | 1.55 | 11.4 | — | 38.2 % | 14.3 % | 9.8 % | 2.7 % | 0.00 | — | -3.3 % | 7 | 0.0 % | 0.0 % | 40.7 | 44.3 % | 0.9 % | 5.0 (1) |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Small-cap stocks with combined earnings and revenue strength: quarterly EPS (earnings per share) ≥ 30% and quarterly revenue ≥ 30% with an EPS rating ≥ 85 — limited to a market cap between $10 million and $500 million.
All scanners are recalculated daily across the entire stock universe — most recently on September 18, 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 7 stocks pass this scanner's criteria (as of September 18, 2026).
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); names after a reverse split (distorted price history) are excluded.
Related scanners
- Ben Bennett: Focus List
- Ben Bennett: Power Screen
- Dan Zanger: Leader
- EPS & Revenue Power
- EPS Acceleration
- Growth Gems
- High Revenue Growth
- Jim Roppel: 20/20 Screen
- Joshua
- Martin Zweig: Growth with Reason
- Matt Caruso: Sales Leader
- Patrick Walker: 30% EPS Growth
- Patrick Walker: 40, 40 Screen
- Quality Growth
- Ted Zhang: Super Stock Universe
- Thomas' Favorites
- Triple-Digit Revenue Growth
- William O'Neil (CAN SLIM)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.